Background Characterizing the prevalence and persistence of symptoms associated with
COVID-19 infection following hospitalization and their impact is essential to planning post-…

Background We compared the efficacy of the antiviral agent, remdesivir, versus standard-of-care
treatment in adults with severe coronavirus disease 2019 (COVID-19) using data from a …

Hydroxychloroquine has been touted as a potential COVID-19 treatment. Tocilizumab, an
inhibitor of IL-6, has also been proposed as a treatment of critically ill patients. In this …

Importance Immune dysregulation contributes to poorer outcomes in COVID-19. Objective
To investigate whether abatacept, cenicriviroc, or infliximab provides benefit when added to …

Importance Current data identifying COVID-19 risk factors lack standardized outcomes and
insufficiently control for confounders. Objective To identify risk factors associated with COVID-…

Background Remdesivir is approved by the US Food and Drug Administration for the treatment
of patients hospitalized with coronavirus disease 2019 (COVID-19) and has been shown …

Here, we report on a phase IIa study to determine the intubation rate, survival, viral clearance,
and development of endogenous Abs in patients with COVID-19 pneumonia treated with …

Background While vaccines have established utility against COVID-19, phase 3 efficacy studies
have generally not comprehensively evaluated protection provided by previous infection …

OBJECTIVES To determine the rate of intubation, overall survival, viral clearance, and the
development of endogenous antibodies in patients with COVID-19 pneumonia treated with …

Importance The pharmacokinetics of abatacept and the association between abatacept
exposure and outcomes in patients with severe COVID-19 are unknown. Objective To …